1-3 of 3
Stephanie L. Verwys
Close
Sort by
Journal Articles

Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

Craig S. Sauter, MD, Stephanie L. Verwys, Susan J. McCall, MSN ANP-BC, Shoshana T. Miller, Amanda I. Courtien, Heiko Schoder, MD, Pamela Harris, MD, Matthew J. Matasar, MD MS, Anas Younes, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2016) 128 (22): 4198.
https://doi.org/10.1182/blood.V128.22.4198.4198
Published: 2016
Journal Articles

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Clinical Trials & Observations
Anita Kumar, Carla Casulo, Joachim Yahalom, Heiko Schöder, Paul M. Barr, Philip Caron, April Chiu, Louis S. Constine, Pamela Drullinsky, Jonathan W. Friedberg, John F. Gerecitano, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Alexandra G. Jacob, Matthew J. Matasar, Gianna N. McArthur, Susan J. McCall, Alison J. Moskowitz, Ariela Noy, Maria L. Palomba, Carol S. Portlock, David J. Straus, Nicholas VanderEls, Stephanie L. Verwys, Joanna Yang, Anas Younes, Andrew D. Zelenetz, Zhigang Zhang, Craig H. Moskowitz
Journal: Blood
Blood (2016) 128 (11): 1458–1464.
https://doi.org/10.1182/blood-2016-03-703470
Published: 2016
Includes: Supplemental data
Journal Articles

Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation

Gunjan L Shah, MDMS, Kurt S Bantilan, MPH, Stephanie L Verwys, BS, Susan J McCall, MSN ANP-BC, Joachim Yahalom, MD, Matthew J. Matasar, MD MS, Alison J Moskowitz, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 520.
https://doi.org/10.1182/blood.V126.23.520.520
Published: 2015